Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

Imaging Technology

MAY 31, 2023

GE HealthCare’s deep-learning-enabled software is revolutionizing image acquisition and reconstruction in MR, CT , X-ray and now PET/CT, empowering clinicians and helping improve patient outcomes. CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. ix Mehranian, A., Walker, M.D.

Nuclear Medicine 98

Nuclear Medicine Healthcare Healthcare IT 98

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. This drug relies on a gallium Ga-68, too, as a diagnostic imaging agent. please insert video here.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. This drug relies on a gallium Ga-68, too, as a diagnostic imaging agent.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98